SCHEMBL6325791

SCHEMBL6325791

Cn1nnc(-c2ccc(NC(=O)Nc3nnc(-c4cc(Cl)cc(Cl)c4O)s3)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 10/20 0.45
RAB9A P51151 6/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
HTT P42858 5/20 0.45
MCL1 Q07820 4/20 0.45
KDM4E B2RXH2 3/20 0.45
HPN P05981 1/20 0.45
POLB P06746 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.43
WRN Q14191 2/20 0.43
ALDH1A1 P00352 1/20 0.43
DNMT1 P26358 1/20 0.43
DUSP3 P51452 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6447175 0.91 NPC1 (0.41) RAB9ASMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL6325956 0.81 BLM (0.53) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6325020 0.81 HPN (0.48) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6324529 0.80 MAPT (0.52) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6325012 0.79 RAB9A (0.55) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6329453 0.79 BLM (0.52) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6323345 0.78 RAB9A (0.50) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6325726 0.78 SMN1; SMN2 (0.44) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6325969 0.78 BLM (0.45) BLMRAB9ASMN1; SMN2HTTMCL1
SCHEMBL6323159 0.77 BLM (0.57) BLMRAB9ASMN1; SMN2HTTMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 US claimed
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 SERPINE1, SERPINC1, SERPINB1 BLM 2929/4885RAB9A 3129/4885SMN1; SMN2 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.